Matteo Santoni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1120416/publications.pdf

Version: 2024-02-01

276 papers	7,361 citations	50244 46 h-index	98753 67 g-index
282 all docs	282 docs citations	282 times ranked	10307 citing authors

#	Article	IF	Citations
1	Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis. Tumori, 2023, 109, 157-163.	0.6	1
2	Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. European Urology Focus, 2022, 8, 514-521.	1.6	64
3	Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 45-51.	0.7	6
4	A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. Anti-Cancer Drugs, 2022, 33, e43-e51.	0.7	2
5	Microbiota and prostate cancer. Seminars in Cancer Biology, 2022, 86, 1058-1065.	4.3	23
6	The Mucolipin TRPML2 Channel Enhances the Sensitivity of Multiple Myeloma Cell Lines to Ibrutinib and/or Bortezomib Treatment. Biomolecules, 2022, 12, 107.	1.8	4
7	Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. Future Oncology, 2022, 18, 739-748.	1.1	11
8	Functional In Vitro Assessment of VEGFA/NOTCH2 Signaling Pathway and pRB Proteasomal Degradation and the Clinical Relevance of Mucolipin TRPML2 Overexpression in Glioblastoma Patients. International Journal of Molecular Sciences, 2022, 23, 688.	1.8	3
9	The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. Critical Reviews in Oncology/Hematology, 2022, 170, 103596.	2.0	76
10	Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 1038.	1.0	3
11	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. European Urology Focus, 2022, 8, 1696-1702.	1.6	17
12	Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. Clinical Genitourinary Cancer, 2022, 20, 285-295.	0.9	5
13	PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: Whatâ€™s Now, Whatâ€™s New, and Whatâ€™s Coming?. Cancers, 2022, 14, 907.	1.7	8
14	Re: Effect of Immunotherapy Time-of-day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-matched Analysis of a Single-centre, Longitudinal Study. European Urology, 2022, 81, 623-624.	0.9	3
15	Chronic Cancer Pain: Opioids within Tumor Microenvironment Affect Neuroinflammation, Tumor and Pain Evolution. Cancers, 2022, 14, 2253.	1.7	17
16	Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis. Clinical Genitourinary Cancer, 2022, 20, 482-487.	0.9	3
17	Time-of-day infusion of immunotherapy in metastatic urothelial cancer (mUC): Should it be considered to improve survival outcomes?. Journal of Clinical Oncology, 2022, 40, e16541-e16541.	0.8	4
18	The prognostic role of nephrectomy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with immunotherapy according to the novel prognostic Meet-URO score: Subanalysis of the Meet-URO 15 study.. Journal of Clinical Oncology, 2022, 40, 4535-4535.	0.8	0

#	Article	IF	Citations
19	Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival. Critical Reviews in Oncology/Hematology, 2022, 176, 103731.	2.0	9
20	Does timing of Immune checkpoint inhibitors (ICIs) administration in first line Metastatic Renal Cell Carcinoma (mRCC) have impact in survival outcomes?. Journal of Clinical Oncology, 2022, 40, e16512-e16512.	0.8	1
21	Coexpression of TRPML1 and TRPML2 Mucolipin Channels Affects the Survival of Glioblastoma Patients. International Journal of Molecular Sciences, 2022, 23, 7741.	1.8	3
22	Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. European Journal of Cancer, 2022, 172, 191-198.	1.3	8
23	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. Clinical Genitourinary Cancer, 2021, 19, e84-e91.	0.9	23
24	Gut microbiota, immunity and pain. Immunology Letters, 2021, 229, 44-47.	1.1	20
25	Predicting future cancer burden in the United States by artificial neural networks. Future Oncology, 2021, 17, 159-168.	1.1	8
26	Treating Prostate Cancer by Antibodyâ€“Drug Conjugates. International Journal of Molecular Sciences, 2021, 22, 1551.	1.8	38
27	An update on investigational therapies that target STAT3 for the treatment of cancer. Expert Opinion on Investigational Drugs, 2021, 30, 245-251.	1.9	13
28	Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. Translational Andrology and Urology, 2021, 10, 1562-1568.	0.6	2
29	Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?. Translational Andrology and Urology, 2021, 10, 1530-1540.	0.6	10
30	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?â€”a narrative review. Translational Andrology and Urology, 2021, 10, 1541-1552.	0.6	6
31	Agent-Based Learning Model for the Obesity Paradox in RCC. Frontiers in Bioengineering and Biotechnology, 2021, 9, 642760.	2.0	4
32	Knock-Down of Mucolipin 1 Channel Promotes Tumor Progression and Invasion in Human Glioblastoma Cell Lines. Frontiers in Oncology, 2021, 11, 578928.	1.3	8
33	Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. International Journal of Molecular Sciences, 2021, 22, 5522.	1.8	12
34	Impact of clinicopathological features on survival in patients treated with immune-based combinations for metastatic urothelial carcinoma: A meta-analysis of randomized clinical trials.. Journal of Clinical Oncology, 2021, 39, e16534-e16534.	0.8	0
35	An update on immunotherapy in uro-oncology. Expert Review of Precision Medicine and Drug Development, 2021, 6, 229-233.	0.4	2
36	Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDCÂrisk groups in metastatic renal cell carcinoma: a meta-analysis. Immunotherapy, 2021, 13, 783-793.	1.0	3

#	Article	IF	Citations
37	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. Oncologist, 2021, 26, 740-750.	1.9	19
38	The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: Whatâ€™s the Story Morning Glory?. International Journal of Molecular Sciences, 2021, 22, 6237.	1.8	15
39	Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy. European Urology, 2021, 79, 887-889.	0.9	3
40	Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. Pathology Research and Practice, 2021, 222, 153440.	1.0	10
41	Quality of life assessment in renal cell carcinomaÂPhase II and III clinical trials published between 2010 and 2020: a systematic review. Future Oncology, 2021, 17, 2671-2681.	1.1	17
42	Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. Cancers, 2021, 13, 3492.	1.7	3
43	Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation. Cancers, 2021, 13, 3471.	1.7	9
44	ERK Phosphorylation Regulates the Aml1/Runx1 Splice Variants and the TRP Channels Expression during the Differentiation of Glioma Stem Cell Lines. Cells, 2021, 10, 2052.	1.8	7
45	Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1237-1243.	1.5	12
46	Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence. Expert Review of Anticancer Therapy, 2021, 21, 1029-1054.	1.1	11
47	Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188547.	3.3	15
48	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Targeted Oncology, 2021, 16, 625-632.	1.7	6
49	An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1-14.	0.9	2
50	Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. European Journal of Cancer, 2021, 154, 120-127.	1.3	71
51	The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors. Diagnostics, 2021, 11, 206.	1.3	15
52	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. Diagnostics, 2021, 11, 138.	1.3	13
53	Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic Revolution. Journal of Clinical Medicine, 2021, 10, 5246.	1.0	2
54	An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. International Journal of Molecular Sciences, 2021, 22, 13519.	1.8	13

#	Article	IF	Citations
55	Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1455-1466.	1.5	7
56	The TRPV2 cation channels: from urothelial cancer invasiveness to glioblastoma multiforme interactome signature. Laboratory Investigation, 2020, 100, 186-198.	1.7	30
57	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. Expert Review of Molecular Diagnostics, 2020, 20, 207-217.	1.5	5
58	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. Expert Review of Molecular Diagnostics, 2020, 20, 141-150.	1.5	14
59	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Cancers, 2020, 12, 84.	1.7	22
60	Designing novel immunocombinations in metastatic renal cell carcinoma. Immunotherapy, 2020, 12, 1257-1268.	1.0	6
61	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. Targeted Oncology, 2020, 15, 495-501.	1.7	28
62	Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER+HER2â˜’Rb wild-type and knock-down in breast cancer cell lines. BMC Cancer, 2020, 20, 1119.	1.1	5
63	Is There a Role for Immunotherapy in Prostate Cancer?. Cells, 2020, 9, 2051.	1.8	65
64	Exploring the Spectrum of Kidney Ciliopathies. Diagnostics, 2020, 10, 1099.	1.3	8
65	Involvement of the TRPML Mucolipin Channels in Viral Infections and Anti-viral Innate Immune Responses. Frontiers in Immunology, 2020, 11, 739.	2.2	30
66	Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. Expert Review of Anticancer Therapy, 2020, 20, 491-501.	1.1	14
67	Emerging Role of Mucolipins TRPML Channels in Cancer. Frontiers in Oncology, 2020, 10, 659.	1.3	18
68	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. Cancers, 2020, 12, 1449.	1.7	72
69	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. Journal of Clinical Medicine, 2020, 9, 1950.	1.0	3
70	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. Cells, 2020, 9, 1495.	1.8	8
71	Renal Cell Carcinoma: genomic landscape and clinical implications. Expert Review of Precision Medicine and Drug Development, 2020, 5, 95-100.	0.4	1
72	Calcium Signaling and the Regulation of Chemosensitivity in Cancer Cells: Role of the Transient Receptor Potential Channels. Advances in Experimental Medicine and Biology, 2020, 1131, 505-517.	0.8	28

#	Article	IF	Citations
73	Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma. Current Drug Targets, 2020, 21, 416-423.	1.0	6
74	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. Current Drug Targets, 2020, 21, 1463-1475.	1.0	10
75	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. Current Drug Targets, 2020, 21, 1664-1671.	1.0	12
76	Staging and Reporting of Renal Cell Carcinomas. , 2020, , 423-436.		0
77	Baseline and early change of neutrophil to lymphocyte ratio (bNLR and Î”NLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study.. Journal of Clinical Oncology, 2020, 38, e17081-e17081.	0.8	0
78	The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesions. Journal of Thoracic Disease, 2020, 12, 7245-7256.	0.6	0
79	Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).. Journal of Clinical Oncology, 2020, 38, TPS762-TPS762.	0.8	1
80	Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study.. Journal of Clinical Oncology, 2020, 38, TPS596-TPS596.	0.8	0
81	BAP1 in solid tumors. Future Oncology, 2019, 15, 2151-2162.	1.1	20
82	Toward a genome-based treatment landscape for renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2019, 142, 141-152.	2.0	15
83	New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant ProstateÂCancer: Meta-Analysis of Efficacy and Safety Outcomes. Clinical Genitourinary Cancer, 2019, 17, e871-e877.	0.9	28
84	Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111â€“28. European Urology Oncology, 2019, 2, 603-604.	2.6	1
85	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. Cancers, 2019, 11, 1225.	1.7	15
86	Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications. BioDrugs, 2019, 33, 613-620.	2.2	23
87	A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. Cancers, 2019, 11, 147.	1.7	15
88	Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud MÃ©jean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842â€“3. European Urology, 2019, 75, e64-e66.	0.9	2
89	Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. Therapeutic Advances in Urology, 2019, 11, 175628721881537.	0.9	7
90	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. Cancers, 2019, 11, 830.	1.7	29

#	Article	IF	Citations
91	The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes. Targeted Oncology, 2019, 14, 247-252.	1.7	17
92	Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. Frontiers in Oncology, 2019, 9, 228.	1.3	20
93	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. Immunotherapy, 2019, 11, 631-643.	1.0	38
94	Microbiome and Cancers, With Focus on Genitourinary Tumors. Frontiers in Oncology, 2019, 9, 178.	1.3	20
95	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. Clinical Drug Investigation, 2019, 39, 503-519.	1.1	26
96	The Human Microbiota and Prostate Cancer: Friend or Foe?. Cancers, 2019, 11, 459.	1.7	38
97	Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. Cancers, 2019, 11, 196.	1.7	23
98	Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma. Annals of Translational Medicine, 2019, 7, S137-S137.	0.7	9
99	The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. International Journal of Molecular Sciences, 2019, 20, 5683.	1.8	26
100	Transient Receptor Potential Cation Channels in Cancer Therapy. Medical Sciences (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382 Td	1.3	27
101	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. Expert Review of Cardiovascular Therapy, 2019, 17, 917-927.	0.6	3
102	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. Cells, 2019, 8, 43.	1.8	38
103	Key players of neuroendocrine differentiation in prostate cancer. Annals of Translational Medicine, 2019, 7, S112-S112.	0.7	1
104	Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. Annals of Translational Medicine, 2019, 7, 572-572.	0.7	28
105	Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. Current Drug Metabolism, 2019, 20, 305-312.	0.7	11
106	Optimizing renal function and outcome of patients with cT2 renal cell carcinoma. Annals of Translational Medicine, 2019, 7, S39-S39.	0.7	0
107	RISE-HEP project part 1: Treatment sequences evaluation in hepatocellular carcinoma cell lines.. Journal of Clinical Oncology, 2019, 37, e15663-e15663.	0.8	0
108	Liquid biopsies in renal cell carcinoma with focus on epigenome analysis. Annals of Translational Medicine, 2019, 7, S194-S194.	0.7	1

#	Article	IF	Citations
109	Association among metabolic syndrome, inflammation, and survival in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 240.e1-240.e11.	0.8	20
110	Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treatment Reviews, 2018, 64, 11-20.	3.4	76
111	Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1869, 78-84.	3.3	150
112	High CTLA-4 expression correlates with poor prognosis in thymoma patients. Oncotarget, 2018, 9, 16665-16677.	0.8	24
113	Quick steps toward precision medicine in renal cell carcinoma. Expert Review of Precision Medicine and Drug Development, 2018, 3, 283-285.	0.4	0
114	Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. Immunotherapy, 2018, 10, 1303-1313.	1.0	3
115	The Identification of Immunological Biomarkers in Kidney Cancers. Frontiers in Oncology, 2018, 8, 456.	1.3	40
116	Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?. Future Oncology, 2018, 14, 2997-2999.	1.1	7
117	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. Frontiers in Oncology, 2018, 8, 397.	1.3	20
118	Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. Anticancer Research, 2018, 38, 5773-5782.	0.5	17
119	Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs in Context, 2018, 7, 1-8.	1.0	63
120	Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. Critical Reviews in Oncology/Hematology, 2018, 131, 1-6.	2.0	10
121	Tivozanib for the treatment of renal cell carcinoma. Expert Opinion on Pharmacotherapy, 2018, 19, 1021-1025.	0.9	16
122	â€œImmuno-Transient Receptor Potential Ion Channelsâ€• The Role in Monocyte- and Macrophage-Mediated Inflammatory Responses. Frontiers in Immunology, 2018, 9, 1273.	2.2	56
123	Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. Frontiers in Oncology, 2018, 8, 221.	1.3	24
124	Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms. PLoS ONE, 2018, 13, e0197035.	1.1	20
125	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. Future Oncology, 2018, 14, 2559-2564.	1.1	6
126	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. Cancer Treatment Reviews, 2018, 68, 80-85.	3.4	27

#	Article	IF	Citations
127	Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors. European Urology, 2018, 74, 521-522.	0.9	41
128	Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. Expert Review of Molecular Diagnostics, 2018, 18, 645-655.	1.5	20
129	Editorial on â€œAdjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trialâ€• Translational Cancer Research, 2018, 7, S74-S76.	0.4	0
130	Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. World Journal of Urology, 2017, 35, 517-526.	1.2	16
131	First-Line PAzopanib in NOnâ€“clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. Clinical Genitourinary Cancer, 2017, 15, e609-e614.	0.9	42
132	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 541.e7-541.e13.	0.8	10
133	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. European Urology Supplements, 2017, 16, 301-308.	0.1	6
134	Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. Oncology, 2017, 92, 269-275.	0.9	5
135	Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach. European Urology Supplements, 2017, 16, 309-315.	0.1	10
136	Healthcare cost of HER2-positive and negative breast tumors in the United States (2012â€“2035). Cancer Treatment Reviews, 2017, 60, 12-17.	3.4	15
137	Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. Cancer Treatment Reviews, 2017, 59, 123-131.	3.4	49
138	Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. Oncotarget, 2017, 8, 23871-23879.	0.8	36
139	Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression. Frontiers in Oncology, 2017, 7, 305.	1.3	20
140	Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner. Oncotarget, 2017, 8, 3380-3395.	0.8	29
141	The TRPV1 ion channel regulates thymocyte differentiation by modulating autophagy and proteasome activity. Oncotarget, 2017, 8, 90766-90780.	0.8	24
142	Emerging Immunotargets in Metastatic Renal Cell Carcinoma. Current Drug Targets, 2016, 17, 771-776.	1.0	20
143	Editorial (Thematic Issue: Emerging Immunotargets in Genitourinary Tumors). Current Drug Targets, 2016, 17, 748-749.	1.0	4
144	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget, 2016, 7, 54564-54571.	0.8	116

#	Article	IF	Citations
145	Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials. PLoS ONE, 2016, 11, e0152079.	1.1	38
146	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. PLoS ONE, 2016, 11, e0151662.	1.1	56
147	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. BioDrugs, 2016, 30, 263-273.	2.2	22
148	Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542â€“3. European Urology, 2016, 70, e69-e70.	0.9	0
149	Handling of the Surgical Specimen and Pathology Reporting of Penile Neoplasms. , 2016, , 275-280.		0
150	Handling of the Surgical Specimen and Pathology Reporting of Malignant Germ Cell and Sex Cord-Stromal Tumors of the Testis. , 2016, , 165-170.		0
151	Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: â€˜Game Overâ€™?. Targeted Oncology, 2016, 11, 431-446.	1.7	7
152	Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. Cancer Treatment Reviews, 2016, 48, 20-24.	3.4	118
153	Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus. Clinical Genitourinary Cancer, 2016, 14, 426-431.	0.9	9
154	Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability. Archives of Pathology and Laboratory Medicine, 2016, 140, 501-502.	1.2	11
155	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. Targeted Oncology, 2016, 11, 143-148.	1.7	152
156	Transplantation of kidneys with tumors. Journal of Nephrology, 2016, 29, 163-168.	0.9	9
157	Prostate cancer: from Gleason scoring to prognostic grade grouping. Expert Review of Anticancer Therapy, 2016, 16, 433-440.	1.1	26
158	Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. Critical Reviews in Oncology/Hematology, 2016, 99, 324-331.	2.0	11
159	Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy. Molecular Diagnosis and Therapy, 2016, 20, 111-117.	1.6	77
160	Metabolic phenotype of bladder cancer. Cancer Treatment Reviews, 2016, 45, 46-57.	3.4	201
161	Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912â€“4. European Urology, 2016, 70, e72-e74.	0.9	6
162	Hyponatremia in cancer patients: Time for a new approach. Critical Reviews in Oncology/Hematology, 2016, 102, 15-25.	2.0	50

#	Article	IF	Citations
163	AR-V7 and prostate cancer: The watershed for treatment selection?. Cancer Treatment Reviews, 2016, 43, 27-35.	3.4	49
164	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. European Urology, 2016, 69, 186-190.	0.9	18
165	Capsaicin triggers autophagic cell survival which drives epithelial mesenchymal transition and chemoresistance in bladder cancer cells in an Hedgehog-dependent manner. Oncotarget, 2016, 7, 50180-50194.	0.8	51
166	Post-transcriptional regulation of 5'-untranslated regions of human Transient Receptor Potential Vanilloid type-1 (TRPV-1) channels: role in the survival of glioma patients. Oncotarget, 2016, 7, 81541-81554.	0.8	15
167	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. Oncotarget, 2016, 7, 33381-33390.	0.8	11
168	Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy. Oncotarget, 2016, 7, 26916-26924.	0.8	44
169	Overexpression of transient receptor potential mucolipin-2 ion channels in gliomas: role in tumor growth and progression. Oncotarget, 2016, 7, 43654-43668.	0.8	48
170	Metabolic Alterations in Renal and Prostate Cancer. Current Drug Metabolism, 2016, 17, 150-155.	0.7	19
171	An Overview of Emerging Immunotargets of Genitourinary Tumors. Current Drug Targets, 2016, 17, 750-756.	1.0	13
172	Emerging Immunotargets in Bladder Cancer. Current Drug Targets, 2016, 17, 757-770.	1.0	9
173	Emerging Immunotargets and Immunotherapies in Prostate Cancer. Current Drug Targets, 2016, 17, 777-782.	1.0	10
174	mTOR Pathway in Renal Cell Carcinoma. , 2016, , 417-428.		0
175	Re: Epithelial-to-mesenchymal Transition in Renal Neoplasms. European Urology, 2015, 68, 736-737.	0.9	10
176	Danger- and pathogen-associated molecular patterns recognition by pattern-recognition receptors and ion channels of the transient receptor potential family triggers the inflammasome activation in immune cells and sensory neurons. Journal of Neuroinflammation, 2015, 12, 21.	3.1	126
177	Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. Future Oncology, 2015, 11, 3159-3166.	1.1	10
178	Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. Prostate, 2015, 75, 1329-1338.	1.2	24
179	HER family Receptor Expression and Prognosis in Pancreatic Cancer. International Journal of Biological Markers, 2015, 30, 327-332.	0.7	9
180	Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. Canadian Urological Association Journal, 2015, 9, 263.	0.3	6

#	Article	IF	Citations
181	Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. Oncotarget, 2015, 6, 36245-36259.	0.8	46
182	Editorial (Mini-Thematic Issue: Morphological and Molecular Backgrounds for Personalized Therapies) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.0	1
183	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. Cancer Treatment Reviews, 2015, 41, 614-622.	3.4	19
184	Lgr5 expression, cancer stem cells and pancreatic cancer: results from biological and computational analyses. Future Oncology, 2015, 11, 1037-1045.	1.1	10
185	Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 303-309.	0.8	16
186	Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. Critical Reviews in Oncology/Hematology, 2015, 96, 81-90.	2.0	64
187	Present and future of personalized medicine in adult genitourinary tumors. Future Oncology, 2015, 11, 1381-1388.	1.1	10
188	Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. Expert Review of Anticancer Therapy, 2015, 15, 1367-1369.	1.1	23
189	Role of STAT3 pathway in genitourinary tumors. Future Science OA, 2015, 1, FSO15.	0.9	58
190	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. Critical Reviews in Oncology/Hematology, 2015, 96, 206-219.	2.0	22
191	Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature. Current Urology Reports, 2015, 16, 3.	1.0	12
192	Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 193, 1905-1910.	0.2	11
193	The route to personalized medicine in bladder cancer: where do we stand?. Targeted Oncology, 2015, 10, 325-336.	1.7	14
194	PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises. Cancer Treatment Reviews, 2015, 41, 114-121.	3.4	161
195	Chromium Exposure and Germinal Embryonal Carcinoma: First Two Cases and Review of the Literature. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2015, 78, 1-6.	1.1	17
196	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. Journal of Experimental and Clinical Cancer Research, 2015, 34, 10.	3.5	65
197	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. Annals of Surgical Oncology, 2015, 22, 2094-2100.	0.7	72
198	Renal cancer in kidney transplanted patients. Journal of Nephrology, 2015, 28, 659-668.	0.9	38

#	Article	IF	Citations
199	Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report. Human Pathology, 2015, 46, 1040-1044.	1.1	7
200	BAP1,PBRM1andSETD2in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Review of Molecular Diagnostics, 2015, 15, 1201-1210.	1.5	78
201	Metabolic alterations in renal cell carcinoma. Cancer Treatment Reviews, 2015, 41, 767-776.	3.4	71
202	KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma. Future Oncology, 2015, 11, 1905-1917.	1.1	11
203	The immunocheckpoints in modern oncology: the next 15 years. Expert Opinion on Biological Therapy, 2015, 15, 917-921.	1.4	24
204	Emerging drugs for the treatment of bone metastasis. Expert Opinion on Emerging Drugs, 2015, 20, 637-651.	1.0	5
205	Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target. Cancer Treatment Reviews, 2015, 41, 569-576.	3.4	41
206	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Targeted Oncology, 2015, 10, 517-522.	1.7	49
207	High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer. Annals of Surgical Oncology, 2015, 22, 1377-1384.	0.7	80
208	Cannabidiol stimulates <scp>A</scp>mlâ€1aâ€dependent glial differentiation and inhibits glioma stemâ€like cells proliferation by inducing autophagy in a <scp>TRPV</scp>2â€dependent manner. International Journal of Cancer, 2015, 137, 1855-1869.	2.3	123
209	Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer, 2015, 15, 195.	1.1	101
210	Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 113.e1-113.e7.	0.8	15
211	Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. Expert Opinion on Investigational Drugs, 2015, 24, 809-824.	1.9	43
212	Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?. Future Oncology, 2015, 11, 107-119.	1.1	16
213	Altering macrophage polarization in the tumor environment: the role of response gene to complement 32. Cellular and Molecular Immunology, 2015, 12, 783-784.	4.8	9
214	Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients. Cellular and Molecular Immunology, 2015, 12, 122-124.	4.8	2
215	Re: Johan Lindberg, Anna Kristiansen, Peter Wiklund, Henrik GrÃ¶nberg, Lars Egevad. Tracking the Origin of Metastatic Prostate Cancer. Eur Urol 2015;67:819â€“22. European Urology, 2015, 68, e134-e135.	0.9	4
216	Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data. Clinical Genitourinary Cancer, 2015, 13, 137-141.	0.9	28

#	Article	IF	Citations
217	Conditional Survival of Patients Treated With First-Line Chemotherapy for Metastatic Urothelial Cancer. Clinical Genitourinary Cancer, 2015, 13, 244-249.	0.9	10
218	The origin of prostate metastases: emerging insights. Cancer and Metastasis Reviews, 2015, 34, 765-773.	2.7	30
219	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 193, 41-47.	0.2	58
220	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. International Journal of Cancer, 2015, 136, 1-10.	2.3	47
221	Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs).. Journal of Clinical Oncology, 2015, 33, e15594-e15594.	0.8	1
222	The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?. PLoS ONE, 2015, 10, e0120427.	1.1	9
223	Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells.. Oncoscience, 2015, 2, 395-409.	0.9	25
224	Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy. Oncotarget, 2015, 6, 19305-19315.	0.8	18
225	Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. Oncotarget, 2015, 6, 32161-32168.	0.8	28
226	Morphologic and Molecular Backgrounds for Personalized Management of Genito-Urinary Cancers: An Overview. Current Drug Targets, 2015, 16, 96-102.	1.0	11
227	Bladder Cancer: Molecular Determinants of Personalized Therapy. Current Drug Targets, 2015, 16, 115-124.	1.0	18
228	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. PLoS ONE, 2014, 9, e105268.	1.1	33
229	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.. Canadian Urological Association Journal, 2014, 8, 121.	0.3	8
230	Cross-talk between alpha1D-adrenoceptors and transient receptor potential vanilloid type 1 triggers prostate cancer cell proliferation. BMC Cancer, 2014, 14, 921.	1.1	35
231	Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy. Gastroenterology Research and Practice, 2014, 2014, 1-9.	0.7	31
232	CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors. BioMed Research International, 2014, 2014, 1-12.	0.9	51
233	Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2014, 92, 208-217.	2.0	29
234	Role of natural and adaptive immunity in renal cell carcinoma response to VEGFRâ€TKIs and mTOR inhibitor. International Journal of Cancer, 2014, 134, 2772-2777.	2.3	57

#	Article	IF	Citations
235	Does prostate acinar adenocarcinoma with Gleason Score 3 + 3 = 6 have the potential to metastasize?. Diagnostic Pathology, 2014, 9, 190.	0.9	10
236	Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell trait. Pathology, 2014, 46, 653-655.	0.3	13
237	Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression. Cells, 2014, 3, 112-128.	1.8	48
238	[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas. ISRN Oncology, 2014, 2014, 1-6.	2.1	10
239	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer and Metastasis Reviews, 2014, 33, 321-331.	2.7	27
240	Thymic neoplasms: An update on the use of chemotherapy and new targeted therapies. A literature review. Cancer Treatment Reviews, 2014, 40, 495-506.	3.4	15
241	Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and metaâ€analysis of clinical trials. International Journal of Cancer, 2014, 135, 763-773.	2.3	43
242	The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid typeâ€2. International Journal of Cancer, 2014, 134, 2534-2546.	2.3	86
243	Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treatment Reviews, 2014, 40, 271-275.	3.4	84
244	Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 221-231.	3.3	46
245	Resiniferatoxin induces death of bladder cancer cells associated with mitochondrial dysfunction and reduces tumor growth in a xenograft mouse model. Chemico-Biological Interactions, 2014, 224, 128-135.	1.7	12
246	Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 630-637.	3.3	38
247	Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. British Journal of Clinical Pharmacology, 2014, 77, 929-938.	1.1	65
248	Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.. Journal of Clinical Oncology, 2014, 32, 471-471.	0.8	8
249	Advances in Transient Receptor Potential Vanilloid-2 Channel Expression and Function in Tumor Growth and Progression. Current Protein and Peptide Science, 2014, 15, 732-737.	0.7	26
250	Expression and Function of the Transient Receptor Potential Ion Channel Family in the Hematologic Malignancies. Current Molecular Pharmacology, 2014, 6, 137-148.	0.7	25
251	Epigenetic, Genetic, and Acquired Regulation of Cav3 T-Type Calcium Channel Expression and Function in Tumor Growth and Progression. , 2014, , 277-295.		0
252	Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2013, 113, 397-401.	1.4	17

#	Article	IF	Citations
253	Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2013, 62, 1757-1768.	2.0	110
254	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. European Journal of Cancer, 2013, 49, 2134-2142.	1.3	60
255	Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. Expert Review of Anticancer Therapy, 2013, 13, 697-709.	1.1	12
256	Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma. BioMed Research International, 2013, 2013, 1-9.	0.9	35
257	The role of transient receptor potential vanilloid type-2 ion channels in innate and adaptive immune responses. Frontiers in Immunology, 2013, 4, 34.	2.2	77
258	Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis, 2013, 34, 48-57.	1.3	201
259	Oncogenic and Anti-Oncogenic Effects of Transient Receptor Potential Channels. Current Topics in Medicinal Chemistry, 2013, 13, 344-366.	1.0	33
260	TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies. CNS and Neurological Disorders - Drug Targets, 2013, 12, 274-293.	0.8	34
261	Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. OncoTargets and Therapy, 2013, 6, 563.	1.0	22
262	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. PLoS ONE, 2013, 8, e83026.	1.1	66
263	Essential Role of Gli Proteins in Glioblastoma Multiforme. Current Protein and Peptide Science, 2013, 14, 133-140.	0.7	53
264	Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?. Current Cancer Drug Targets, 2013, 13, 313-325.	0.8	8
265	VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. Anticancer Research, 2013, 33, 5017-22.	0.5	12
266	Present and Future of Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: Analysis of Hematologic Toxicity. Recent Patents on Anti-infective Drug Discovery, 2012, 7, 104-110.	0.5	20
267	Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder. Advances in Urology, 2012, 2012, 1-5.	0.6	22
268	Functional role of Tâ€type calcium channels in tumour growth and progression: prospective in cancer therapy. British Journal of Pharmacology, 2012, 166, 1244-1246.	2.7	51
269	A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy. Journal of Translational Medicine, 2012, 10, 90.	1.8	12
270	Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. Oncology Letters, 2012, 4, 799-801.	0.8	10

#	Article	IF	Citations
271	The transient receptor potential vanilloidâ€2 cation channel impairs glioblastoma stemâ€like cell proliferation and promotes differentiation. International Journal of Cancer, 2012, 131, E1067-77.	2.3	71
272	Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy. Current Perspectives and Novel Strategies. Recent Patents on Biomarkers, 2012, 2, 99-106.	0.3	1
273	Capsaicin promotes a more aggressive gene expression phenotype and invasiveness in null-TRPV1 urothelial cancer cells. Carcinogenesis, 2011, 32, 686-694.	1.3	58
274	New deals on the transcriptional and post-transcriptional regulation of TRP channel target genes during the angiogenesis of glioma. Journal of Experimental and Integrative Medicine, 2011, 1, 221.	0.1	6
275	TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. Carcinogenesis, 2010, 31, 794-803.	1.3	101
276	New Insight on the Role of Transient Receptor Potential (TRP) Channels in Driven Gliomagenesis Pathways. , 0, , .		1